世界の抗凝血剤市場2022-2031：産業分析、規模、シェア、成長、動向、予測

• 英文タイトル：Anticoagulants Market (Drug Class: Factor XA Inhibitors [NOAC/DOAC], Heparins, and Direct Thrombin inhibitors, and Vitamin K Antagonists) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

• レポートコード：MRC2301D010 • 出版社/出版日：Transparency Market Research / 2022年11月4日 • レポート形態：英文、PDF、175ページ • 納品方法：Eメール • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥869,250 (USD5,795)	▷ お問い合わせ
Multi User	￥1,319,250 (USD8,795)	▷ お問い合わせ
Corporate License	￥1,769,250 (USD11,795)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

Transparency Market Research社の市場調査書では、世界の抗凝血剤市場について調査・分析を行い、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、主要インサイト、薬物クラス別（ファクターXA阻害剤（NOAC/DOAC）、ヘパリン、直接トロンビン阻害剤、ビタミンK拮抗薬）分析、投与経路別（経口、注射）分析、疾患別（深部静脈血栓症、肺塞栓症、心房細動・心筋梗塞、虚血性脳卒中、その他）分析、流通チャネル別（病院薬局、小売薬局、オンライン薬局）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などの内容を整理しました。並びに、当書に掲載されている企業情報には、Bayer AG、Boehringer Ingelheim International GmbH.、Bristol Myers Squibb、Daiichi Sankyo Company、Sanofi、Johnson & Johnson、Pfizer, Inc.などが含まれています。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・主要インサイト ・世界の抗凝血剤市場規模：薬物クラス別 - ファクターXA阻害剤（NOAC/DOAC）の市場規模 - ヘパリンの市場規模 - 直接トロンビン阻害剤の市場規模 - ビタミンK拮抗薬の市場規模 ・世界の抗凝血剤市場規模：投与経路別 - 経口抗凝血剤の市場規模 - 注射抗凝血剤の市場規模 ・世界の抗凝血剤市場規模：疾患別 - 深部静脈血栓症における場規模 - 肺塞栓症における場規模 - 心房細動・心筋梗塞における場規模 - 虚血性脳卒中における場規模 - その他疾患における場規模 ・世界の抗凝血剤市場規模：流通チャネル別 - 病院薬局チャネルの市場規模 - 小売薬局チャネルの市場規模 - オンライン薬局チャネルの市場規模 ・世界の抗凝血剤市場規模：地域別 - 北米の抗凝血剤市場規模 - ヨーロッパの抗凝血剤市場規模 - アジア太平洋の抗凝血剤市場規模 - 中南米の抗凝血剤市場規模 - 中東・アフリカの抗凝血剤市場規模 ・競争状況

Anticoagulants Market – Scope of Report
TMR’s report on the global anticoagulants market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global anticoagulants market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global anticoagulants market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the anticoagulants market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global anticoagulants market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global anticoagulants market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global anticoagulants market.

The report delves into the competitive landscape of the global anticoagulants market. Key players operating in the global anticoagulants market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global anticoagulants market profiled in this report.

RESEARCH METHODOLOGY

The research methodology will be a combination of exhaustive primary and secondary research to analyze the market anticoagulants.

Secondary Research

Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.

Secondary research sources that we typically refer, but are not limited to:

Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market

Specific Secondary Sources:

Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound

Primary Research

During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.

We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:

Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies

Participants who typically take part in such a process include, but are not limited to:

Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals

List of primary participants, but not limited to:

Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.

Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.

Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:

Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities

Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.

レポート目次

---

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Anticoagulants Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Anticoagulants Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Bn)
5. Key Insights
5.1. Key industry events (mergers & acquisitions, product launches, partnerships, etc.)
5.2. Overview on the Novel Oral Anticoagulants (NOACs)
5.3. Epidemiology of the Key Diseases
5.4. Covid-19 Pandemic Impact on the Industry
6. Global Anticoagulants Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Class, 2017–2031
6.3.1. Factor XA Inhibitors (NOAC/DOAC)
6.3.2. Heparins
6.3.3. Direct Thrombin Inhibitors
6.3.4. Vitamin K Antagonists
6.4. Market Attractiveness Analysis, by Drug Class
7. Global Anticoagulants Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Route of Administration, 2017–2031
7.3.1. Oral
7.3.2. Injectable
7.4. Market Attractiveness Analysis, by Route of Administration
8. Global Anticoagulants Market Analysis and Forecast, by Indication
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Indication, 2017–2031
8.3.1. Deep Vein Thrombosis
8.3.2. Pulmonary Embolism
8.3.3. Atrial Fibrillation & Heart Attack
8.3.4. Ischemic Stroke
8.3.5. Others
8.4. Market Attractiveness Analysis, by Indication
9. Global Anticoagulants Market Analysis and Forecast, by Distribution Channel
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by Distribution Channel, 2017–2031
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Market Attractiveness Analysis, by Distribution Channel
10. Global Anticoagulants Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness Analysis, by Region
11. North America Anticoagulants Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Class, 2017–2031
11.2.1. Factor XA Inhibitors (NOAC/DOAC)
11.2.2. Heparins
11.2.3. Direct Thrombin Inhibitors
11.2.4. Vitamin K Antagonists
11.3. Market Value Forecast, by Route of Administration, 2017–2031
11.3.1. Oral
11.3.2. Injectable
11.4. Market Value Forecast, by Indication, 2017–2031
11.4.1. Deep Vein Thrombosis
11.4.2. Pulmonary Embolism
11.4.3. Atrial Fibrillation & Heart Attack
11.4.4. Ischemic Stroke
11.4.5. Others
11.5. Market Value Forecast, by Distribution Channel, 2017–2031
11.5.1. Hospital Pharmacies
11.5.2. Retail Pharmacies
11.5.3. Online Pharmacies
11.6. Market Value Forecast, by Country, 2017–2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Drug Class
11.7.2. By Route of Administration
11.7.3. By Indication
11.7.4. By Distribution Channel
11.7.5. By Country
12. Europe Anticoagulants Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2017–2031
12.2.1. Factor XA Inhibitors (NOAC/DOAC)
12.2.2. Heparins
12.2.3. Direct Thrombin Inhibitors
12.2.4. Vitamin K Antagonists
12.3. Market Value Forecast, by Route of Administration, 2017–2031
12.3.1. Oral
12.3.2. Injectable
12.4. Market Value Forecast, by Indication, 2017–2031
12.4.1. Deep Vein Thrombosis
12.4.2. Pulmonary Embolism
12.4.3. Atrial Fibrillation & Heart Attack
12.4.4. Ischemic Stroke
12.4.5. Others
12.5. Market Value Forecast, by Distribution Channel, 2017–2031
12.5.1. Hospital Pharmacies
12.5.2. Retail Pharmacies
12.5.3. Online Pharmacies
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Italy
12.6.5. Spain
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Drug Class
12.7.2. By Route of Administration
12.7.3. By Indication
12.7.4. By Distribution Channel
12.7.5. By Country/Sub-region
13. Asia Pacific Anticoagulants Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2017–2031
13.2.1. Factor XA Inhibitors (NOAC/DOAC)
13.2.2. Heparins
13.2.3. Direct Thrombin Inhibitors
13.2.4. Vitamin K Antagonists
13.3. Market Value Forecast, by Route of Administration, 2017–2031
13.3.1. Oral
13.3.2. Injectable
13.4. Market Value Forecast, by Indication, 2017–2031
13.4.1. Deep Vein Thrombosis
13.4.2. Pulmonary Embolism
13.4.3. Atrial Fibrillation & Heart Attack
13.4.4. Ischemic Stroke
13.4.5. Others
13.5. Market Value Forecast, by Distribution Channel, 2017–2031
13.5.1. Hospital Pharmacies
13.5.2. Retail Pharmacies
13.5.3. Online Pharmacies
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Drug Class
13.7.2. By Route of Administration
13.7.3. By Indication
13.7.4. By Distribution Channel
13.7.5. By Country/Sub-region
14. Latin America Anticoagulants Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Class, 2017–2031
14.2.1. Factor XA Inhibitors (NOAC/DOAC)
14.2.2. Heparins
14.2.3. Direct Thrombin Inhibitors
14.2.4. Vitamin K Antagonists
14.3. Market Value Forecast, by Route of Administration, 2017–2031
14.3.1. Oral
14.3.2. Injectable
14.4. Market Value Forecast, by Indication, 2017–2031
14.4.1. Deep Vein Thrombosis
14.4.2. Pulmonary Embolism
14.4.3. Atrial Fibrillation & Heart Attack
14.4.4. Ischemic Stroke
14.4.5. Others
14.5. Market Value Forecast, by Distribution Channel, 2017–2031
14.5.1. Hospital Pharmacies
14.5.2. Retail Pharmacies
14.5.3. Online Pharmacies
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Drug Class
14.7.2. By Route of Administration
14.7.3. By Indication
14.7.4. By Distribution Channel
14.7.5. By Country/Sub-region
15. Middle East & Africa Anticoagulants Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Drug Class, 2017–2031
15.2.1. Factor XA Inhibitors (NOAC/DOAC)
15.2.2. Heparins
15.2.3. Direct Thrombin Inhibitors
15.2.4. Vitamin K Antagonists
15.3. Market Value Forecast, by Route of Administration, 2017–2031
15.3.1. Oral
15.3.2. Injectable
15.4. Market Value Forecast, by Indication, 2017–2031
15.4.1. Deep Vein Thrombosis
15.4.2. Pulmonary Embolism
15.4.3. Atrial Fibrillation & Heart Attack
15.4.4. Ischemic Stroke
15.4.5. Others
15.5. Market Value Forecast, by Distribution Channel, 2017–2031
15.5.1. Hospital Pharmacies
15.5.2. Retail Pharmacies
15.5.3. Online Pharmacies
15.6. Market Value Forecast, by Country/Sub-region, 2017–2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Drug Class
15.7.2. By Route of Administration
15.7.3. By Indication
15.7.4. By Distribution Channel
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player – Competition Matrix (by tier and size of companies)
16.2. Market Share/Ranking Analysis, by Company, 2021
16.3. Company Profiles
16.3.1. Bayer AG
16.3.1.1. Company Overview
16.3.1.2. Product Portfolio
16.3.1.3. SWOT Analysis
16.3.1.4. Strategic Overview
16.3.2. Boehringer Ingelheim International GmbH
16.3.2.1. Company Overview
16.3.2.2. Product Portfolio
16.3.2.3. SWOT Analysis
16.3.2.4. Strategic Overview
16.3.3. Bristol Myers Squibb
16.3.3.1. Company Overview
16.3.3.2. Product Portfolio
16.3.3.3. SWOT Analysis
16.3.3.4. Strategic Overview
16.3.4. Daiichi Sankyo Company
16.3.4.1. Company Overview
16.3.4.2. Product Portfolio
16.3.4.3. SWOT Analysis
16.3.4.4. Strategic Overview
16.3.5. Sanofi
16.3.5.1. Company Overview
16.3.5.2. Product Portfolio
16.3.5.3. SWOT Analysis
16.3.5.4. Strategic Overview
16.3.6. Johnson & Johnson
16.3.6.1. Company Overview
16.3.6.2. Product Portfolio
16.3.6.3. SWOT Analysis
16.3.6.4. Strategic Overview
16.3.7. Pfizer, Inc.
16.3.7.1. Company Overview
16.3.7.2. Product Portfolio
16.3.7.3. SWOT Analysis
16.3.7.4. Strategic Overview

---